British Porphyria Association’s Post

According to the Pew Charitable Trusts, 340B discounts are only 1.4% of gross U.S. drug sales and the impact of 340B on manufacturers' revenue is under 2%. Yet, the discounts generated from the program allow safety-net hospitals to provide crucial services to their patients. *This was before the drug manufacturers started blocking 340B at contract pharmacies for the most vulnerable patients and taking away patients choice! But salaries with top pharma CEOs in 2023 soared: Joaquin Duato (Johnson & Johnson): Total Pay: $28.42 million David A. Ricks (Eli Lilly): Total Pay: $26.57 million Richard Francis (Teva Pharmaceutical Industries Ltd.): Total Pay: $25.71 million Richard A. Gonzalez (AbbVie): Total Pay: $25.66 million Robert A. Bradway (Amgen): Total Pay: $22.64 million Daniel P. O’Day (Gilead Sciences): Total Pay: $22.61 million Albert Bourla (Pfizer): Total Pay: $21.56 million Reshma Kewalramani (Vertex Pharmaceuticals): Total Pay: $20.59 million Robert M. Davis (Merck): Total Pay: $20.27 million Giovanni Caforio (Bristol Myers Squibb): Total Pay: $19.66 million

Give the gift of life through organ donation.🫀 Unimarck Pharma honors World Organ Donation Day and supports this vital cause.🌟 . . . . #unimarckpharma#unimarck #organdonation #donatelife #worldorgandonationday #organdonor #giftoflife #organdonationawareness #savelives #beanorgandonor #organdonationmatters #donateorgans #lifesavingdonation #wellness #pharmaceuticalindustry #pharmacompany #pharmaindustry #pharmaceuticals #pharma #pharmacompanies #manufacturers #thirdpartyservices #thirdpartymanufacturing #thirdpartymanufacturers #contractmanufacturer #manufacturingunit

Hemogenyx Pharmaceuticals up 9% after it receives further investment from partner Prevail @HemoGenyx #LSE #OTC #HEMO #HOPHF. Shares in Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) rose 9% after it secured a new $350,000 investment from Prevail Partners, an investment fund, as it gears up for important clinical trials. The investment, which comes at a price significantly above the company’s current share value, follows a similar injection of funds in September. The money will support Hemogenyx’s work on its HEMO-CAR-T therapy, a cutting-edge treatment for blood cancers. The company plans to start trials for pediatric patients with acute myeloid leukaemia... http://ow.ly/jcR0105KFFA

Teva Pharmaceuticals USA, Inc. and Teva Neuroscience, Inc. (collectively Teva) have agreed to pay $425 million to resolve allegations that Teva paid kickbacks via two co-pay assistance foundations in violation of the Anti-Kickback Statute (AKS) and False Claims Act. The government’s complaint, filed in 2020, alleged that from 2006 to 2017, Teva manipulated the co-pay foundation assistance system by conspiring with multiple third parties, including a specialty pharmacy and two allegedly independent co-pay assistance foundations, to direct its supposed charitable payments specifically to patients taking its own multiple sclerosis drug, Copaxone. At the same time, Teva steadily raised Copaxone’s price by thousands of dollars. The United States alleges that this conduct violated the AKS and caused the submission of false claims to Medicare. The settlement was reached after the government’s review of Teva’s financial disclosures concerning its financial condition. This settlement is the latest in a string of enforcement actions against pharmaceutical companies that allegedly used third-party foundations as conduits to pay kickbacks. Since 2017, the United States Attorney’s Office in Massachusetts has collected over $1.4 billion from this enforcement initiative. The U.S. Attorney’s Office has also settled with four of the third-party foundations that participated in this conduct and a specialty pharmacy. Today’s resolution with Teva is the largest co-pay assistance settlement to date. Read more here: https://lnkd.in/em5TBQ83

Are you heading to Asembia's AXS24 Summit? Schedule a meeting with a Dedham Group expert to learn how our market access oncology and specialty therapeutics strategic consulting services can help you. https://ow.ly/b6qA50QYJVm #Asembia24

Two years ago I lost my father to Pulmonary Fibrosis. He was king of the pun, kind, and curious. He was a retired principal who built a second career as an antiques dealer and as Grandpa extraordinare. After his diagnosis I thought I'd be able to help my parents navigate services and the health system. After all, I had many years under my belt supporting caregivers professionally, many years advocating for neurodiverse children, children with rare diseases, and those with medical complexity. Armed with a deep understanding of our national health system (read: national health insurance plan)'s strengths and limitations, I was not surprised when we had to ask for a compassionate review to afford his medication. I was not surprised at the difficulty in getting homecare. I was not surprised at the distance he had to travel for specialist appointments. But nothing prepares you for when that becomes personal. I am deeply proud of all the professionals from pharmacists, family doctor(luckily he had one!), to all the specialists. I am proud of my dad for keeping a smile and twinkle in his eye to the end. But I call upon policy makers to build a health system that is ready to meet the needs of those with rare disorders. Building a health system ready for anything is not easy and it is not cheap - but our health system is capable of greatness, and our citizens are worth the cost. I've never known so many incredible clinicians and researchers ready to meet the moment. We just need governments ready to make the long term investment in funding and designing a health system to meet the needs of all Canadians. #healthcare #leadership #rarediseases

Thoughts on this? >> Natick non-profit news: Dion's Foundation for Children with Rare Diseases forges partnership; Cookbook recipes sought; Embrace a Family fundraiser tix available - Natick Report >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #biotech #pharmaceutical #competitivemarketing

Join us October 3rd for our next webinar where top industry leaders will share their hard-earned insights and strategies on extending your cash runway, negotiating better deals, and maximizing resources without stifling growth. With speakers who have been in your shoes, this interactive session will provide actionable tips you can implement immediately to help your startup reach its next milestone. Submit questions in registration or via the Q&A function day of. We look forward to seeing you and "chatting" next week! #lifescience #startups #fundraising #biotech

🚀Exciting News!!! Today, we announced that Lantern Pharma Inc. (Nasdaq: LTRN) ’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in #Glioblastoma from the #FDA   Why is it exciting... 📍Fast Track Designation is designed to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need. 📍Fast Track Designation for LP-184 (STAR-001) recognizes Glioblastoma (#GBM) as a serious condition impacting more than 13,000 U.S. adults each year and approximately 300,000 globally. 📍A phase 1b/2a clinical trial for recurrent GBM is targeted to start in late 2024/early 2025. 📍LP-184, which will be developed as STAR-001 for CNS and other neuro-oncology indications by Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma, has the potential to be the first new drug for treating GBM in more than 20 years. Read the full release: https://bit.ly/3YmdfQ2 Visit our website: www.lanternpharma.com Visit Starlight's website: www.starlightthera.com

Happy #WorldBloodDonationDay from Jeevan Scientific! Blood donations are crucial for saving lives and advancing medical research. We honor and thank all the heroes who donate blood. Consider becoming a donor and help support those in need. Every drop counts! #BloodDonation #GiveBlood #LifeSaver #medicine #medical #pharmaceuticals #pharma #clinical #clinicaltrials #JSTL #Jeevanscientifictechnologylimited #Jeevanscientific #clinicalresearch